// App-Quantinova.ai

1691 : TMPRSS2:ERG fusion enhances osteoblastic phenotype of prostate cancer bone metastases

Researchers

Presenter

  • Carine Delliaux

Principal Investigators

  • Tian V. Tian

  • Mathilde Bouchet

  • Anais Fradet

  • Nathalie Vanpouille

  • Anne Flourens

  • Rachel Deplus

  • Xavier Leroy

  • Yvan de Launoit

  • Edith Bonnelye

  • Martine Duterque-Coquillaud

Medical Centers

  • Univ. Lille, CNRS, Institut Pasteur de Lille, UMR - M T Mechanisms of Tumorigenesis and Target Therapies, Lille, France

  • Univ. Lille, CNRS, Institut Pasteur de Lille, UMR - M T Mechanisms of Tumorigenesis and Target Therapies, Lille, France Center for Genomic Regulation, Barcelona, Spain

  • Unite INSERM U Universite Claude Bernard Lyon , Lyon, France

  • Univ. Lille, CNRS, Institut Pasteur de Lille, UMR - M T Mechanisms of Tumorigenesis and Target Therapies, Lille, France Institut Laboratory of Cancer Epigenetics, Faculty of Medicine, ULB, Brussels, Belgium

  • Institut de Pathologie-Centre de Biologie-Pathologie-Centre Hospitalier Regional et Universitaire, Lille, France.

Locations

  • France

  • Spain

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • ETS transcription factor ERG

  • Transmembrane Serine Protease 2

  • TMPRSS2:ERG

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved